




NEW ONSET OF DIABETES MELLITUS IN INDIAN RENAL TRANSPLANT RECIPIENT-A 
RETROSPECTIVE STUDY 
 
DHARMIK D PATELa*, KETAN P MODIb, ANIL K PATELc, VIPUL CHAUDHARYd 
aPhD Scholar, School of Pharmacy, R K University, Rajkot, bAssociate Professor, B K Modi government college, Rajkot, cConsultant 
Nephrologists, Care Hospital, Surat, d
 Received: 12 Jun 2015 Revised and Accepted: 11 Jul 2015 
ABSTRACT 
Objective: To identify incidence and determinant of new-onset of diabetes after transplant (NODAT) in Indian renal transplant recipients. 
Methods: In this study Indian renal transplant recipients who were not diabetic before transplant and underwent kidney transplantation between 
July 2004 and June 2011 were enrolled. Various data of all transplant patients including age, gender, body weight, pre transplant Hepatitis C virus 
(HCV), Hepatitis B virus (HBV) infection status, Human Leukocyte Antigens (HLA) mismatch, maintenance immunosuppressant drug, usage of 
antibodies, anti rejection treatment, patients and graft survival, post-transplant infection including HCV, HBV, Herpes and Cytomegalo virus (CMV) 
infection were noted down. In this study patients who had taken anti diabetic medicine beyond 1 month were considered as diabetic. 
Results: Total 537 renal transplant recipients were enrolled in the study. Patients age (P<0.0001), body weight (P=0.042) and HLA mismatch 
(P=0.015) were significantly effected on prevalence of NODAT. Other parameters like sex (P=0.862), type of donor (P=0.191), pre transplant HBV 
(P=0.285) and pre transplant HCV (P=0.201) were not significantly affecting development of NODAT. NODAT prevalence was not significantly 
affected by different Calciurine Inhibitors (CNIs) (P=0.079), antibodies (P=0.671) and by anti rejection therapy (P=0.115). Post-transplant infection 
was significantly higher in NODAT patients (P=0.022) and mainly among them CMV infection was prevalent (P=0.002). Other infections were found 
similar in patients with or without NODAT. NODAT was not significantly affecting patients survival (P=0.828) and graft survival (P=0.101).  
Conclusion: Age more than 45 years, body weight more than 70 kilogram, HLA mismatch, tacrolimus treatment are significantly affecting 
development of NODAT in Indian transplant recipients. NODAT is strongly associated with development of post-transplant infection and among 
them CMV infection was prevalent. 
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INTRODUCTION 
In renal transplant patients, survival time has gradually increased 
because of the improved survival rate during the perioperative 
period and enhancements in treatment with anti rejection drugs [1-
3]. So now a day’s more attention received on long-term 
complications and the quality of life of transplant recipients. 
New-onset diabetes after transplantation (NODAT) is frequent 
metabolic complication after renal transplantation and is the major 
factor leading to dysfunction of the renal graft and patient death and 
is a risk factor for cardiovascular diseases in these patients [4, 5]. 
NODAT severely affects the quality of life and long-term survival 
rate of renal transplant recipients [6-9]. So international consensus 
guidelines 2003 considered NODAT is one of the risk factor for renal 
transplant patients [10].  
The reported incidence varies by the definition of diabetes and the 
type of immunosuppressive medications used. The cumulative 
incidence of NODAT by the end of the first year has generally been 
found to be 10–30 % in adults receiving cyclosporine (CyA) or 
tacrolimus plus corticosteroids [11, 12]. 
Historically, the reported incidence of NODAT in kidney transplant 
recipients varied widely based on different definitions of the 
disorder in older studies.  
They were summarized and nineteen of these older reports in a Meta-
analysis indicated that an incidence of NODAT ranging from 2 % to 50 
% in the first post-transplant year [13]. Varying definitions probably 
also accounted for the fact that some [14, 15], but not all [13] 
reviews indicate that the incidence of NODAT has increased during 
the past three decades. So we performed this study to identify the 
incidence and determinant of new-onset of diabetes after transplant 
(NODAT) in Indian renal transplant recipients. 
MATERIALS AND METHODS 
Subjects 
This retrospective study was conducted at Muljibhai Patel Urological 
Hospital, Nadiad, Gujarat. For conduction of this study; we had taken 
permission from the dean of Hospital. In this study, we analyzed the 
records of 632 patients who underwent renal transplant at study 
center from July 2004 to June 2011. All patients followed till their 
follow up interval completed on or before June 2012. The reports of 
patients who were belong to foreign nationality, patients whose data 
were not available and those patients who suffered from diabetes 
before transplant was excluded. The remaining 537 non-diabetic 
patients who underwent a renal transplant were included for 
analysis.  
Collection of data 
Basic preoperative data included general data (gender, age, body 
weight, Human Leukocyte Antigens (HLA) mismatch) preoperative 
examination, primary renal diseases and source of donor kidney 
were collected. Data on the condition during the perioperative 
period included intra operative the patient’s immune induction; 
initial immunosuppressant regimen and acute rejection (AR) 
treatment were collected. Postoperative follow-up data included 
patient’s survival, graft survival, infections like hepatitis B virus 
(HBV)/hepatitis C virus (HCV)/cytomegalovirus (CMV) markers, 
herpes infection, postoperative immunosuppressant maintenance 
regimen was reported. 
All patients received a triple drug regimen comprising of calciurine 
inhibitor (CNI) (Tacrolimus/cyclosporine), antiproliferative (myco-
phenolate mofetil/azathioprine) and glucocorticoids as a postoperative 
immunosuppressant treatment. Dose of these drugs was used as per 
standard protocol and continued throughout follow up period.  
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All patients underwent periodic follow-up after surgery as required 
by the follow-up system at our medical center (frequent outpatient 
department visits and indoor stay when indicated). 
Definition of NODAT 
NODAT was defined as a requirement of drugs (oral agents with or 
without insulin) for at least one month to control blood sugar. Blood 
sugar was monitored at each visit to the hospital and at home by self 
monitoring by glucometer. 
Statistical analysis 
Data was analyzed using SPSS software. Chi square test and Z test 
were applied. P value below 0.05 was considered as significant.  
RESULTS 
General preoperative conditions of patients with and without 
NODAT 
Characteristic of renal transplant donors and recipients are shown 
in table 1.  
 
Table 1: Characteristic of renal transplant donors and 
recipients 




Males 433 (80.6 %) 
Female 104 (19.4 %) 
Native Kidney Disease 
Undetermined 259 (48.2 %) 
CGN 120 (22.3 %) 
CTID 43 (8.0 %) 
Hypertensive nephropathy 24 (4.5 %) 
Nephrolithiasis 18 (3.4 %) 
Reflux Nephropathy 24 (4.5 %) 
Other 49 (9.1 %) 
Viral infection 
Hepatitis B 25 (4.7 %) 
Hepatitis C 29 (5.4 %) 
Donor 
Donor Age 46.6±10.24 
Donor male 193 (35.9 %) 
Donor female 344 (64.1 %) 
Type of Donor 
Cadaveric Donor 7 (1.3 %) 
Living Donor 530 (98.7 %) 
HLA mismatch 
0 37 (6.9 %) 
1 48 (8.9 %) 
2 111 (20.7 %) 
3 144 (26.8 %) 
4 86 (16.0 %) 
5 62 (11.5 %) 
6 49 (9.1 %) 
 
Prevalence of NODAT  
Out of 537 patients, 182 patients developed NODAT during follow 
up period. So prevalence rate for NODAT was 33.89 % in our study. 
The prevalence rate of NODAT is not significantly different between 
male and female transplant recipients (P=0.862) and incidence rate 
of NODAT was 33.72 % and 34.62 % respectively.  
Effect of age and weight  
Among this 537 non diabetic recipients, 99 recipients age was more 
than or equal to 45 years and incidence rate of NODAT was 
significantly higher in this age than recipients age below 45 years 
(P<0.0001). Same higher incidence rate was also observed in 
patients having weight above 70 kilogram as compare to patients 
with weight less than or equal to 70 kilogram (P=0.042). 
NODAT and type of donor  
The proportion of NODAT in recipients with cadaveric donor kidney 
was not significantly higher than patients with living donor kidney 
(P=0.191).  
In our study, we found that Human Leukocyte Antigens (HLA) 
mismatch has significantly affected the development of NODAT 
between recipients who had HLA mismatch with donor (P=0.015).  
Influence of immunosuppressant drug  
As per institutional protocol all patients received intravenous 
methylprednisolone single dose before engraftment followed by oral 
prednisolone which was tapered gradually. Selected patients (31.8 %) 
also received Anti thymocyte globulin (ATG) (6.3 %), Basiliximab 
(12.3 %), or Daclizumab (13.2 %), as an induction agent. Prevalence 
rate of NODAT in antibody treated patients was 33.3 % while in 
patients without antibody treated patients it was 34.1 % and it was 
not statistically significant between these two groups (P=0.671).  
If considering NODAT in two different CNIs (Tacrolimus and 
cyclosporine) treated patients as a maintenance regimen then we 
did not find either of Tacrolimus or cyclosporine (P=0.079) affect 
significantly on the prevalence of NODAT after renal transplant 
patients.  
Among these transplant patients few patients were developing 
rejection during hospitalization or in follow up visits. These patients 
were treated with a higher dose of steroids or combination of 
steroids and ATG as an anti rejection therapy. But we were not 
finding any statistically significant difference between this two 
groups for the development of NODAT (P=0.115). 
Influence of infection on NODAT  
Non-significant difference was also observed in our study in 
recipients who were treated with Hepatitis C virus (HCV) or 
hepatitis B virus (HBV) infection before transplant than patients 
without pre transplant HCV or HBV infection history (P= 0.201 and 
P=0.285 respectively).  
Influence of NODAT on infection  
Comparing the infection ratio in NODAT patients with recipients 
without NODAT it shows that the prevalence rate of infection is 
higher in NODAT patients than patients without NODAT (P=0.022). 
Prevalence Cytomegalo virus (CMV) infection in NODAT patients 
was statistically significant than control group (P=0.002). 
Prevalence of HBV infection (P=0.404), HCV infection (P=0.901) and 
herpes infection (P=0.063) was not statistically significant in 
between NODAT group and control group.  
DISCUSSION 
The prevalence rate of diabetes in patients with kidney transplant is 
significantly elevated compared with the normal population [16]. A 
study conducted by Brzezinska B et al. on 209 in renal transplant 
recipients underwent oral glucose tolerance test shows that the 
prevalence rates of NODAT, impaired glucose tolerance, and 
impaired fasting glucose were 19 %, 14 %, and 17 %, respectively 
[17]. While other studies conducted by Chaoyang LV et al. on 
Chinese population shows that prevalence rate of NODAT was 20.32 
% in kidney transplant recipients [18]. But in our study we found 
that 33.89 % renal transplant patients developed NODAT after 
transplant which is higher than literature. In our study prevalence 
rate of NODAT is higher it may be due to all recipients were 
administered steroids as a part of immuno supression protocol and 
Indian population are more prone to diabetes than other [19]. 
Older age is the strongest and most consistent risk factor for NODAT 
in kidney transplantation and is reported in the majority of studies 
[15, 20, 21]. Study conducted by Cosio et al. on 2078 allograft 
recipients showed that those who were older than 45 years were 2.9 
times more likely to develop diabetes [14]. Data from the US Renal 
Data System (USRDS) showed that first kidney transplant recipients 
who were between 45 and 59 year had a relative risk (RR) for 
NODAT of 1.9 (95 % confidence interval (CI) 1.73 to 2.09; P 
<0.0001), whereas patients who were above 60 year had a risk of 2.6 
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(95 % CI 2.32 to 2.92; P<0.0001) [15]. In our study, it was reflected 
that patients with more than 45 years age having more chances to 
develop NODAT than patients with age less than 45 years 
(P<0.0001). One of the reasons for development of NODAT in older 
age recipients is they required the higher dose of 
immunosuppressant drug to suppress their immune system for 
survival of graft as compared to younger recipients.  
Body weight is one of the factors for the development of NODAT 
after transplantation. One study conducted to identify the effect of 
weight in renal transplant patients shows that individuals whose age 
was>45 years and weight was>70 kg had an OR of 6.4 (95 % CI 1.2–
33.4) for the development of NODAT [22]. In our study, we also 
found same higher rate of NODAT in patients having weight more 
than 70 kilogram. 
Diabetes has been reported to be more common in patients with 
hepatitis C than in other types of liver disease in the general 
population [23, 24]. The mechanism of diabetes caused after virus 
infection is not clear, but it has been assumed that insulin resistance 
and defects in islet cell secretion are both involved. In patient having 
HCV-positive at the time of transplantation, one year incidence of 
NODAT was 25.6 % compared with HCV-negative patients (15.4 %; 
P<0.0001) [15]. A meta-analysis of clinical studies that involved 
2502 kidney recipients concluded that the adjusted odds ratio for 
NODAT was 3.97 (95 % CI 1.83 to 8.61) [25]. In renal transplant 
recipients, NODAT associated with a positive hepatitis C virus (HCV) 
serology ranges from 1.3 to 1.4 [26]. But in our study we are not 
finding any significant difference between recipients who were 
treated for HCV infection before transplant than patients with no 
history of HCV infection. If considering pre transplant HBV positive 
effect on transplant recipients than our results shows that there is 
no any significant observation found between two groups. 
Type of donor means living or cadaver also effect on incidence of 
NODAT after renal transplant. Two different studies conducted by 
Kuo HT et al. and Chaoyang LV et al. shows that recipients of 
cadaveric donor kidneys are at higher risk for NODAT [27, 18]. But 
in our results we have not found any significant difference between 
renal transplant recipients who receive kidney from cadaver donor 
and who receive from Living donor.  
HLA mismatch is also one of the risk factors for the NODAT after 
kidney transplant. Study conducted by Kasiske BL et al. using united 
stated renal system of year 1996 to 2000 shows that recipients 
having 6 HLA mismatch donor had a relative risk (RR) for NODAT of 
1.33 (95 % confidence interval [CI] 1.07 to 1.58; P<0.0001) as 
compare to recipients having 0 HLA mismatch donor [15]. In our 
study, we also found significant difference in HLA mismatch 
patients. Incidence rate of NODAT is in higher recipients having 
higher HLA mismatch because they require higher dose of 
immunosuppressant drug at the time of transplant and after 
transplant for the survival of graft and patients as compare to less 
HLA mismatch patients. 
Effect of immunosuppressant drug on NODAT 
Glucocorticoids 
Glucocorticoids induce a state of insulin resistance, and also lead to 
increasing hepatic gluconeogenesis which leads to increase the 
chances of diabetes [28]. In our study, we found all patients were 
administered the higher dose of glucocorticoids on the day of 
transplant as an inducing agent and this may be one of the reasons for 
the higher prevalence rate of NODAT in our study. Because of this 
reason in many centers steroid avoidance protocol is implemented but 
same steroid avoidance protocol is not found in our study. 
Postoperative withdrawal of corticosteroid therapy is controversial in 
clinical studies of a renal transplant but it is commonly recognized that 
postoperative short-term pulsed therapy and low-dose maintenance 
therapy are not only safe but also reduce the risk of NODAT [29]. Study 
conducted by Ghisdal L et al. and Maes BD et at shows that pulse 
glucocorticoid therapy given in the context of acute rejection 
treatment remains an independent risk factor of NODAT [30, 31]. But 
in our study we are not able find whether the anti rejection treatment 
is an independent risk factor for NODAT or not. 
Calcineurin inhibitor 
CNIs are diabetogenic by inducing a defect in insulin secretion by 
interfering with the nuclear factor of activated T-cell signaling in β-
cells of pancreas. This pathway triggers the expression of genes 
critical for β-cell function, including at least six genes mutated in 
hereditary forms of monogenic diabetes [32]. Registry analyses, 
meta-analyses, and the prospective study conducted by Vincenti et 
al. showed that the risk of NODAT was significantly higher in 
patients on tacrolimus versus cyclosporine [15, 26, 33-35]. 
Tacrolimus induces a reversible suppression of insulin secretion at 
the level of insulin messenger RNA transcription, mediated by the 
binding of the drug to FK506 binding protein-12 and a subsequent 
inhibition of calcineurin in the β-cell [36]. The high level of FK506 
binding protein-12 present in pancreatic β-cells might explain why 
tacrolimus more profoundly inhibits insulin secretion than 
cyclosporine and this is the reason for the higher prevalence rate of 
NODAT in tacrolimus treated recipients. But in our study we have 
not found a significant difference for NODAT between patients 
treated with tacrolimus or cyclosporine and reason for that is not 
identified. 
In our study, all patients were administered steroids and calciurine 
inhibitor so it is difficult to identify whether NODAT is due to 
steroid, calciurine inhibitor or both. It may be possible to reduce the 
overall risk of NODAT by avoiding or reducing the doses of 
immunosuppressive medications that are particularly likely to cause 
NODAT in patients with higher risk factors. But, the risk of acute 
rejection must also be included in the selection of 
immunosuppressive medications. 
Graft survival and patient’s survival 
The development of NODAT has also been shown to be associated 
with an adverse impact on patient survival and an increased risk of 
graft rejection and graft loss and also increased the incidence rate of 
infectious complications. A study conducted on 173 renal transplant 
recipients, one year patient survival rate in patients with NODAT 
versus those without NODAT were 83 % versus 98 %, respectively 
(P<0.01) [22]. Data from the United Renal Data System, consisting of 
over 11,000 Medicare beneficiaries who received primary kidney 
transplants between 1996 and 2000 demonstrated that compared to 
“no diabetes”, NODAT was associated with a 63 % increased risk of 
graft failure (P<0.0001), a 46 % increased risk of death-censored 
graft failure (P<0.0001) and an 87 % increased risk of mortality 
(P<0.0001) [15] while in contrast to this reports, a retrospective 
analysis of the UNOS/OPTN database (involving patients 
transplanted between 2004–2007) failed to demonstrate the 
negative impact of NODAT on transplant survival or CV mortality 
during a median follow-up of 548 days [37
In our investigation, the frequency and days of hospitalization due to 
infections in patients with NODAT are higher than those of patients 
without NODAT. Use of immunosuppressants after an organ 
transplant reduces the resistance of the body to exogenous 
infections and recipients having concomitant NODAT are more 
vulnerable to infections. This may be due to the lower chemotaxis, 
]. In our study, we found 
same result means we did not found any significant effect of NODAT 
on patients and graft survival. 
Antibody induction 
A study conducted by Fu. L. Luan et al. shows that in induction 
medication, recipient who given ATG has higher rate of NODAT then 
alemtuzumab, Anti IL-2 receptor antibody and other and this 
incidence of NODAT in ATG treated Patients was 17 % while 10 % 
and 15.5 % for alemtuzumab, Anti IL-2 receptor antibody 
respectively [38] while our results were contraindicating to this 
results. Our results shows that patients who were given basiliximab 
as an induction agent along with glucocorticoids having a high 
incidence rate of NODAT than patients treated with declizumab and 
ATG with glucocorticoids (37.88 % with basiliximab Vs 35.29 % in 
ATG Vs 28.17 % in Declizumab). But in our results it is not clearly 
found that any of these antibodies may have significantly affected on 
the prevalence rate of NODAT.  
Infection 
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migration and phagocytic function of neutrophil granulocytes in 
diabetic patients compared with healthy people [39]. In our study, 
we found that patients with NODAT having a higher incidence rate of 
infection as compared to patients without NODAT. Among other 
infection incidence rate of CMV infection is significantly higher in 
NODAT patients than patients without NODAT. But for other 
infections like HCV, Herpes and HBV, we have not found statistically 
significant difference in patients with NODAT then without NODAT. 
Infection after NODAT may affect the survival rate of the patients so 
it is required preventing infection after transplantation. 
CONCLUSION  
Our results show that the prevalence rate of NODAT is higher in 
Indian patients than other recipients. In our study, we are not 
finding any significant effect of pre transplant HCV and HBV 
infection on NODAT. Our result shows a significant effect of 
recipient’s age, body weight and HLA mismatch on the NODAT. Type 
of donor had no effect on NODAT. In our results, we are not finding a 
significant effect of different CNI agent, use of antibody and anti 
rejection therapy on NODAT. In our results, we found that infection 
is significantly higher in NODAT patients and mainly CMV infection 
but in other infections like HBV, HCV and Herpes infection we are 
not able find any significant different.  
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